Crystal Bioscience and Boehringer Ingelheim Announce Multiple Target Antibody Discovery Collaboration

EMERYVILLE, CA and INGELHEIM, Germany -- (Business Wire) -- Crystal Bioscience Inc. (Crystal) and Boehringer Ingelheim (BI) announced today that they have entered into an agreement to collaborate on the discovery and development of therapeutic antibodies. Crystal Bioscience will apply its proprietary gel encapsulated microenvironment (GEM) and chicken immunization platforms to discover antibodies to multiple targets selected by BI, with the goal of discovering different development candidates that may result in new or better therapies. BI will have the option to conduct the further development and commercialization of the antibodies.  Under the terms of the agreement, Crystal will receive an upfront technology access fee and research funding for each program, and may receive technical success fees, option exercise fees, and other downstream payments.

“We appreciate the confidence that BI has placed in our team and technology following on the success of our prior work together.  We are very pleased to have a partner with the depth and breadth of experience of BI in the development of therapeutic products” said Robert J. Etches, President and CEO of Crystal Bioscience.

“Crystal is an innovative addition to our biotherapeutics efforts. Crystal can deliver monoclonal antibodies generated in chicken, which offer access to new target space.  We are pleased to extend our relationship with this proven partner and technology" said Jeffrey Hanke, SVP Research and Global Head Biotherapeutics."

About Crystal Bioscience Inc.

Crystal Bioscience is a privately held company that was founded in 2008 to develop a world-class therapeutic antibody discovery engine using chickens. Its platform is “powered by evolution,” exploiting the large phylogenetic distance between mammals and birds to generate a diverse array of antibodies to human targets that have proven intractable in mammalian and other discovery platforms. Crystal’s patented platform provides the unique ability to isolate monoclonal antibodies from immunized chickens, and can screen simultaneously for specificity and biological activity. It has led to the discovery of bioactive monoclonals directed against difficult targets, including GPCRs and ion channels. Chicken antibodies often recognize both human and mouse orthologs, which can simplify early stages of drug development where mouse disease models are used. The depth of screening provided by the GEM assay in combination with the breadth of the antibody repertoire in immunized birds provides access to an unparalleled source of affinity matured antibodies with therapeutic potential.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information please visit www.boehringer-ingelheim.com

Crystal Bioscience Media Contact
Rob Etches
Crystal Bioscience, Inc.
President & CEO
Phone: (510) 250-7798
e-mail
website